Mission: Lifeline Award

June 16th, 2017

June 16, 2017 — JPS has been awarded the American Heart Association’s 2017 Quality Achievement Award for maintaining the highest standards of care for heart attack patients.

Most patients at JPS have blood flow restored to the heart well within 90 minutes of arrival, earning JPS the association’s 2017 Mission: Lifeline Silver Plus Quality Achievement Award, the highest level of Mission: Lifeline recognition that JPS could receive after its first year of participation in the program.

The AMI Task Force drives process improvements in heart attack care.

The Mission: Lifeline program is intended to drive improvement in care for patients with the most time-sensitive emergencies, including heart attack and stroke. Both are caused by blocked arteries — a blockage that prevents blood flow to the heart, in the case of heart attack, or to the brain in stroke. Treatments continue to improve, but are only effective if done quickly, before permanent damage occurs.

Care for heart attack and stroke patients at JPS took a leap forward with the 2015 opening of a state-of-the-art vascular surgery unit, known as Invasive Labs, where vascular surgeons and cardiologists open blocked blood vessels with catheters, clot-busting drugs and stents. Successful outcomes depend on a hospital-wide effort, however, as a surgeon can do little for a patient who lingers too long in the emergency room.

Process improvements driven by the AMI Task Force at JPS have cut down the time it takes to recognize a heart attack in progress and move those patients along quickly toward Invasive Labs for procedures.

Hospitals in the heart association’s Mission: Lifeline program submit data to a national database. Special recognition is awarded for meeting a bundle of core measures in the treatment of patients with the most life-threatening type of heart attack, known as STEMI. A STEMI (ST-elevation myocardial infarction) occurs when a cardiac artery is completely blocked, signaling impending death of heart muscle. Rapid response to STEMIs requires quick recognition of signs and symptoms, including the tell-tale heart rhythm seen on EKG.

Core measures include door-to-device time under 90 minutes, which JPS achieved consistently throughout 2016.

The heart association recognized JPS for “applying the most up-to-date evidence-based treatment guidelines to improve patient care and outcomes in the community you serve.”

 

State-of-the-art Invasive Labs opened in 2015

Share this article!